FDA clears Merck & Co's Emend Injection for CINV

US drug major Merck & Co says that the Food and Drug Administration has approved Emend (fosaprepitant dimeglumine) for Injection, a new intravenous therapy for the prevention of chemotherapy-induced nausea and vomiting. Emend for Injection is an intravenous prodrug of the oral formulation of Emend (aprepitant), which means that when it is administered, fosaprepitant is rapidly converted in the body to aprepitant. The novel agent is approved for use in combination with other antiemetic medicines for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately-emetogenic and highly-emetogenic cancer chemotherapy, including high-dose cisplatin.